Promising Outlook for aTyr Pharma: Phase 3 Study Progress and Potential Stock Upside

JonesTrading analyst Soumit Roy maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $22.00.

Soumit Roy’s rating is based on aTyr Pharma’s promising progress in their Phase 3 EFZO-FIT study for pulmonary sarcoidosis, which is expected to yield topline data by the third quarter of 2025. The study’s design, which includes a robust sample size and a focus on reducing steroid use, positions the company well for potential positive outcomes. The anticipation of presenting baseline patient characteristics at the ATS conference further adds to the company’s transparency and potential investor confidence.
Roy’s valuation model suggests significant upside potential for aTyr Pharma’s stock, with a possibility of tripling its current trading price upon successful Phase 3 results. This projection is based on a conservative peak sales multiple and a discounted cash flow analysis. The company’s previous Phase 1/2 trial results, which demonstrated positive trends in steroid reduction and improved patient outcomes, bolster confidence in the ongoing Phase 3 study’s success.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.